International Journal of Clinical Research

Objective To investigate the therapeutic difference of peripheral neurotoxicity (CIPN) in this treatment. Methods This study was included in patients with grade I peripheral neurotoxicity (CIPN) caused by chemotherapy with paclitaxel (paclitaxel injection, albumin-bound paclitaxel, liposomal paclitaxel, docetaxel), hospitalized in the hematology oncology department of Baoji TCM Hospital and Baoji Central Hospital between November 2023 and March 2025. All patients were divided into control group (oral study group) and study group (group A: collateral therapy, group B: herbal treatment). The treatment cycle was performed for 4 weeks. Neurotoxicity grading was assessed using NCI-CTCAE V5.0, pain relief rate (RR) was double assessed using the WHO pain efficacy criteria combined with NRS digital grading, and quality of life was assessed using the Neurotoxic Quality of Life Evaluation Scale (FACT / GOG-Ntx scale) of the American Cancer Treatment Functional Evaluation System (FACT). Results After treatment, study group A (exiting group) was significantly better than group B (88.3% and 86.7%) and control group (85.0%, 85.0% and 72.1%). Study group A has achieved significant advantages in improving neurotoxicity grade, pain reduction and improving quality of life. In terms of safety, no serious adverse events occurred in each group. Conclusion The bloodletting therapy can effectively alleviate the peripheral neurotoxicity caused by paclitaxel chemotherapy, reduce pain and improve the quality of life of patients, which is worth clinical application.

Paclitaxel; Docetaxel; Peripheral neurotoxicity; Collateral release; External use of chinese medicine; Clinical efficacy